What the Cancer Community Actually Needs from Psychedelic Care

Psilocybin-assisted psychedelic care for cancer needs to center on meaning, identity, belonging, and mortality, not only depression, trauma, or neuroplasticity. The author, a cancer survivor and founder of the Survivorship Collective, argues that cancer survivorship often brings existential fear of recurrence and psychological dislocation that standard medical care tends to treat the tumor but not the terror. She describes her own psilocybin experience as helping her face mortality without collapsing and links this to evidence from clinical research showing reduced cancer-related depression and anxiety after psilocybin. She calls for a survivor-led model that avoids power dynamics, ego-led facilitation, and spiritual bypassing. Survivors, she says, benefit from steady engagement with mortality, humility from facilitators, and sessions that combine evidence with culture and ceremony, plus continuity through preparation and long-term integration in community settings. As access expands, she emphasizes that scaling psychedelic care will require attention to access, cost, training, and ethical and cultural accountability, rather than isolated interventions or purely clinical delivery.